ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 168

Examining the Role of IFN-I and Langerhans Cell ADAM17 in Lupus Photosensitivity

Keila Veiga1, Noa Schwartz 2, William Shipman 1, Marvin Sandoval 3, Thomas Li 1, Yurii Chinenov 1, David Oliver 1, Ali Jabbari 4, James Krueger 5, Sarah Taber 1, Niroshana Anandasabapathy 6 and Theresa Lu 1, 1Hospital for Special Surgery, New York, 2Albert Einstein College of Medicine/Montefiore Medical Center, New York, 3Weill Cornell Graduate School of Medical Sciences, New York, 4University of Iowa, Iowa City, 5Rockefeller Center, New York, 6Weill Cornell Medicine, New York

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: adam17, interferons, Langerhans cell, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Saturday, May 2, 2020

Title: Poster Session 3

Session Type: ACR Abstract Session

Session Time: 4:15PM-5:15PM

Background/Purpose: Photosensitivity resulting in inflammatory skin lesions is a hallmark of cutaneous lupus.  Lesions can be disfiguring and have a negative impact on quality of life.  Understanding photosensitivity is critical to developing better treatment. Our lab showed ADAM17, a metalloprotease found on Langerhans cells (LCs), is activated by UVR and is critical for limiting UVR-induced keratinocyte apoptosis and skin inflammation through cleavage and activation of epidermal growth factor receptor (EGFR) ligands.  Two photosensitive SLE models showed reduced LC ADAM17 expression with evidence for dysfunction in human SLE, suggesting that photosensitivity is at least in part due to dysfunctional LCs.  A prominent IFN signature has been documented in the blood and skin of SLE patients and could be an upstream mediator of ADAM17.  We thus hypothesized that Type I IFN downregulates LC ADAM 17 activity resulting in photosensitive rash in SLE.  To test this hypothesis, we examined gene expression patterns in non-lesional skin of human and murine lupus and are also examining the gene expression signature in ADAM17-deficient LCs.

Methods: Transcriptomics of non-lesional skin from discoid lupus (DLE) and healthy controls and of MRL and MRL/lpr mice were compared.  Human data was gathered from unpublished data from Krueger et al (2014) using microarray in DLE lesions compared to psoriasis and healthy skin.  We performed RNA seq on non-lesional skin of MRL and MRL/lpr mice.  Data were analyzed in R using edgeR. Gene set analyses were performed with QuSAGE and plots were generated using a custom Shiny platform developed by the HSS Genomics Center.   To examine whether LCs show an IFN-I regulated gene signature, we are currently sorting LCs from both UVR-exposed and non-exposed WT and Adam 17 fl/fl Langerin Cre mice for RNA seq.  Pending IRB approval, using the method of suction blistering to sample immune cells in the skin, our plan is to gather LCs from the skin of SLE patients to determine LC ADAM17 activity and whether this correlates with interferon signature via RNA seq.

Results: IFN-I regulated genes were among the most differentially regulated genes in non-lesional skin in both human and the MRL/lpr lupus mouse model.  Many interferon regulated genes were found to be highly expressed in both (Fig 1A, D).  Pathway analysis further showed that IFN-I-regulated genes were among the most differentially regulated pathways in disease vs control skin for both humans and mice (Fig 1B, E).   Preliminary results from the analysis of ADAM17fl/fl Langerin Cre mice are expected in the next several months.

Conclusion: Microarray results suggest an elevated IFN signature in non-lesional skin of DLE patients with a similar IFN signature found in MRL/lpr mice via RNA seq. We anticipate we will detect a reduction in ADAM17 activity in non-lesional skin of SLE patients and find a correlation with IFN signature, supporting a role for IFN-I in dysregulating ADAM17 in SLE photosensitivity.  These findings could help to understand why type I IFN targeted therapies are having success in SLE skin disease and may lead to targeting ADAM17 for lupus. We hope to determine whether the gene signature associated with ADAM17 deficiency can be seen in other inflammatory skin conditions, such as JDM.

Figure 1. IFN_I signature is found in non_lesional human SLE skin and in MRL/lpr mice. A_C. Microarray of non_lesional human cutaneous lupus and healthy skin. A. Heat map of top 25 DEGs. B. Differentially expressed pathways. Circled symbol is IFN_I pathway. C. IFN_I pathway gene expression. D_F. RNAseq of non_lesional MRL/+ and MRL/lpr skin. D. Heat map of top 25 DEGs. E. Differentially expressed pathways. Circled symbol is IFN_I pathway. F. IFN_I pathway gene expression.


Disclosure: K. Veiga, None; N. Schwartz, None; W. Shipman, None; M. Sandoval, None; T. Li, None; Y. Chinenov, None; D. Oliver, None; A. Jabbari, None; J. Krueger, None; S. Taber, None; N. Anandasabapathy, None; T. Lu, None.

To cite this abstract in AMA style:

Veiga K, Schwartz N, Shipman W, Sandoval M, Li T, Chinenov Y, Oliver D, Jabbari A, Krueger J, Taber S, Anandasabapathy N, Lu T. Examining the Role of IFN-I and Langerhans Cell ADAM17 in Lupus Photosensitivity [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/examining-the-role-of-ifn-i-and-langerhans-cell-adam17-in-lupus-photosensitivity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/examining-the-role-of-ifn-i-and-langerhans-cell-adam17-in-lupus-photosensitivity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology